Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction

被引：2

作者：

Buller, Dylan M. ^{[1
]}

Antony, Maria ^{[2
]}

Ristau, Benjamin T. ^{[1
,3
]}

机构：

[1] UConn Hlth, Div Urol, Farmington, CT USA

[2] Univ Connecticut, Sch Med, Farmington, CT USA

[3] UConn Hlth, Div Urol, 263 Farmington Ave, Farmington, CT 06030 USA

来源：

ONCOTARGETS AND THERAPY | 2023年 / 16卷

关键词：

renal cell carcinoma; adjuvant therapy; targeted therapy; immunotherapy; radiation; PRIMARY KIDNEY CANCER; EARLY BREAST-CANCER; PHASE-III TRIAL; STEREOTACTIC ABLATIVE RADIOTHERAPY; POSTOPERATIVE PROGNOSTIC NOMOGRAM; RADIOSURGERY ONCOLOGY CONSORTIUM; BODY RADIOTHERAPY; OPEN-LABEL; INTERFERON-ALPHA; RANDOMIZED-TRIAL;

D O I：

10.2147/OTT.S393296

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Locally and regionally advanced renal cell carcinoma (RCC) can recur at high rates even after visually complete resection of primary disease. Both targeted therapies and immunotherapies represent potential agents that might help reduce recurrence of RCC in these patients. This paper reviews the current body of evidence defining their potential impact and examines the large Phase III randomized clinical trials that have been performed to assess the safety and efficacy of these systemic therapies in the adjuvant setting. Given that the findings from these trials have been predominantly negative, this paper also explores the role of other potential adjuvant agents, including single and combination agent targeted therapies and immunotherapies, whose use is currently limited to metastatic RCC. Finally, the use of radiation therapy and the use of advanced imaging modalities in RCC are also considered.

引用

页码：49 / 64

页数：16

共 152 条

[11] Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Tomczak, P. ;

Park, S. H. ;

Venugopal, B. ;

Ferguson, T. ;

Chang, Y. -H. ;

Hajek, J. ;

Symeonides, S. N. ;

Lee, J. L. ;

Sarwar, N. ;

Thiery-Vuillemin, A. ;

Gross-Goupil, M. ;

Mahave, M. ;

Haas, N. B. ;

Sawrycki, P. ;

Gurney, H. ;

Chevreau, C. ;

Melichar, B. ;

Kopyltsov, E. ;

Alva, A. ;

Burke, J. M. ;

Doshi, G. ;

Topart, D. ;

Oudard, S. ;

Hammers, H. ;

Kitamura, H. ;

Bedke, J. ;

Perini, R. F. ;

Zhang, P. ;

Imai, K. ;

Willemann-Rogerio, J. ;

Quinn, D. I. ;

Powles, T. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (08) :683-694

[12] Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial [J].

Choueiri, T. K. ;

Larkin, J. ;

Pal, S. ;

Motzer, R. J. ;

Rini, B., I ;

Venugopal, B. ;

Alekseev, B. ;

Miyake, H. ;

Gravis, G. ;

Bilen, M. A. ;

Hariharan, S. ;

Chudnovsky, A. ;

Ching, K. A. ;

Mu, X. J. ;

Mariani, M. ;

Robbins, P. B. ;

Huang, B. ;

di Pietro, A. ;

Albiges, L. .

ESMO OPEN, 2021, 6 (03)

[13] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Powles, T. ;

Burotto, M. ;

Escudier, B. ;

Bourlon, M. T. ;

Zurawski, B. ;

Juarez, V. M. Oyervides ;

Hsieh, J. J. ;

Basso, U. ;

Shah, A. Y. ;

Suarez, C. ;

Hamzaj, A. ;

Goh, J. C. ;

Barrios, C. ;

Richardet, M. ;

Porta, C. ;

Kowalyszyn, R. ;

Feregrino, J. P. ;

Zolnierek, J. ;

Pook, D. ;

Kessler, E. R. ;

Tomita, Y. ;

Mizuno, R. ;

Bedke, J. ;

Zhang, J. ;

Maurer, M. A. ;

Simsek, B. ;

Ejzykowicz, F. ;

Schwab, G. M. ;

Apolo, A. B. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09) :829-841

[14]

Choueiri TK, 2020, ANN ONCOL, V31, P1030, DOI [10.1016/j.annonc.2020.04.010, 10.1016/j.annoc.2020.04.010]

[15] Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Escudier, B. ;

Powles, T. ;

Mainwaring, P. N. ;

Rini, B. I. ;

Donskov, F. ;

Hammers, H. ;

Hutson, T. E. ;

Lee, J-L ;

Peltola, K. ;

Roth, B. J. ;

Bjarnason, G. A. ;

Geczi, L. ;

Keam, B. ;

Maroto, P. ;

Heng, D. Y. C. ;

Schmidinger, M. ;

Kantoff, P. W. ;

Borgman-Hagey, A. ;

Hessel, C. ;

Scheffold, C. ;

Schwab, G. M. ;

Tannir, N. M. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19) :1814-1823

[16]

Choueiri TK, 2022, J CLIN ONCOL, V40

[17] Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. [J].

Choueiri, Toni K. ;

Tomczak, Piotr ;

Park, Se Hoon ;

Venugopal, Balaji ;

Ferguson, Tom ;

Symeonides, Stefan N. ;

Hajek, Jaroslav ;

Chang, Yen-Hwa ;

Lee, Jae-Lyun ;

Sarwar, Naveed ;

Thiery-Vuillemin, Antoine ;

Gross-Goupil, Marine ;

Mahave, Mauricio ;

Haas, Naomi B. ;

Sawrycki, Piotr ;

Xu, Lei ;

Imai, Kentaro ;

Willemann-Rogerio, Jacqueline ;

Quinn, David I. ;

Powles, Thomas .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)

[18] Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial [J].

Choueiri, Toni K. ;

Halabi, Susan ;

Sanford, Ben L. ;

Hahn, Olwen ;

Michaelson, M. Dror ;

Walsh, Meghara K. ;

Feldman, Darren R. ;

Olencki, Thomas ;

Picus, Joel ;

Small, Eric J. ;

Dakhil, Shaker ;

George, Daniel J. ;

Morris, Michael J. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06) :591-+

[19] Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial [J].

Choueiri, Toni K. ;

Escudier, Bernard ;

Powles, Thomas ;

Tannir, Nizar M. ;

Mainwaring, Paul N. ;

Rini, Brian I. ;

Hammers, Hans J. ;

Donskov, Frede ;

Roth, Bruce J. ;

Peltola, Katriina ;

Lee, Jae Lyun ;

Heng, Daniel Y. C. ;

Schmidinger, Manuela ;

Agarwal, Neeraj ;

Sternberg, Cora N. ;

McDermott, David F. ;

Aftab, Dana T. ;

Hessel, Colin ;

Old, Christian Scheff ;

Schwab, Gisela ;

Hutson, Thomas E. ;

Pal, Sumanta ;

Motzer, Robert J. .

LANCET ONCOLOGY, 2016, 17 (07) :917-927

[20] A preoperative clinical prognostic model for non-metastatic renal cell carcinoma [J].

Cindolo, L ;

de la Taille, A ;

Messina, G ;

Romis, L ;

Abbou, CC ;

Altieri, V ;

Rodriguez, A ;

Patard, JJ .

BJU INTERNATIONAL, 2003, 92 (09) :901-905

← 1 2 3 4 5 6 7 8 9 10 →